Article Versions Notes

Ruggiero R, Balzano N, Nicoletti MM, di Mauro G, Fraenza F, Campitiello MR, Rossi F, Capuano A. Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma^®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System. Pharmaceuticals. 2024; 17(3):394. https://doi.org/10.3390/ph17030394

Ruggiero, Rosanna, Nunzia Balzano, Maria Maddalena Nicoletti, Gabriella di Mauro, Federica Fraenza, Maria Rosaria Campitiello, Francesco Rossi, and Annalisa Capuano. 2024. "Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma^®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System" Pharmaceuticals 17, no. 3: 394. https://doi.org/10.3390/ph17030394

Ruggiero, R., Balzano, N., Nicoletti, M. M., di Mauro, G., Fraenza, F., Campitiello, M. R., Rossi, F., & Capuano, A. (2024). Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma^®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System. Pharmaceuticals, 17(3), 394. https://doi.org/10.3390/ph17030394